GlassScriptPhysician profile
Roy J Culotta
NPI 1851331458
$4,309.62
in general payments reported to CMS, 2019-2025
24 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.90 · 2020: $233 · 2021: $1,002 · 2022: $192 · 2023: $1,390 · 2024: $418 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,806 · Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,805.75 |
| Food and Beverage | $1,022.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,033.87 | 2023-2025 | Da Vinci Surgical System |
| Ethicon INC. | $976.18 | 2021-2023 | Monarch Platform |
| Merck Sharp & Dohme LLC | $227.45 | 2020-2025 | Winrevair |
| Insmed, INC. | $109.00 | 2021-2025 | Arikayce |
| Genzyme Corporation | $97.39 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $93.47 | 2019-2021 | |
| Abbvie INC. | $87.17 | 2021-2023 | Teflaro, Dalvance, Avycaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.69 | 2020-2025 | Ofev |
| Glaxosmithkline, LLC. | $81.28 | 2019-2025 | Nucala |
| Allergan, INC. | $80.89 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.80 | 2021-2024 | |
| Verona Pharma, INC. | $49.61 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $44.88 | 2023-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $37.22 | 2024 | Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $32.59 | 2023 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Getinge USA Sales, LLC | $29.46 | 2019 | |
| United Therapeutics Corporation | $29.05 | 2025 | Tyvaso |
| Grifols USA, LLC | $28.42 | 2025 | Prolastin-C Liquid |
| Scpharmaceuticals INC. | $25.43 | 2024 | |
| Mylan Specialty L.P. | $22.89 | 2024 | Yupelri |
| Baxter Healthcare | $21.73 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Astellas Pharma US INC | $19.30 | 2021 | |
| Philips North America LLC | $15.74 | 2024 | (Ak6) Vest Therapy |
| Janssen Pharmaceuticals, INC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Culotta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.